Germline truncating-mutations in BRCA1 and MSH6 in a patient with early onset endometrial cancer

BMC Cancer

Volumn 12, Issue , 2012, Pages

  Kast, Karin ^a   Neuhann, Teresa M ^b,c   Görgens, Heike ^a   Becker, Kerstin ^b   Keller, Katja ^a   Klink, Barbara ^b   Aust, Daniela ^a   Distler, Wolfgang ^a   Schröck, Evelin ^b   Schackert, Hans K ^a  

^a UNIVERSITY HOSPITAL CARL GUSTAV CARUS   (Germany)

^b DRESDEN UNIVERSITY OF TECHNOLOGY   (Germany)

^c Medical Genetic Center   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ARGININE; BRCA1 PROTEIN; BRCA2 PROTEIN; DNA; MISMATCH REPAIR PROTEIN PMS2; PROTEIN MLH1; PROTEIN MSH2; PROTEIN MSH6; SERINE;

ADULT; AGE; AMINO ACID SUBSTITUTION; ANAMNESIS; ARTICLE; CANCER RISK; CANCER STAGING; CASE REPORT; CAUCASIAN; COLPOTOMY; DENATURING HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; DNA DETERMINATION; ENDOMETRIUM CANCER; FAMILY HISTORY; FAMILY STUDY; FEMALE; GENE MUTATION; GENETIC ANALYSIS; GENETIC COUNSELING; GERM LINE; HEREDITARY BREAST AND OVARIAN CANCER SYNDROME; HETEROZYGOSITY; HISTOPATHOLOGY; HUMAN; HYSTERECTOMY; IMMUNOHISTOCHEMISTRY; MSH6 GENE; PATIENT REFERRAL; TUMOR SUPPRESSOR GENE;

AGE OF ONSET; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; DNA-BINDING PROTEINS; ENDOMETRIAL NEOPLASMS; FEMALE; GENETIC PREDISPOSITION TO DISEASE; GERM-LINE MUTATION; HUMANS; MIDDLE AGED; PEDIGREE; UBIQUITIN-PROTEIN LIGASES;

EID: 84869161931     PISSN: None     EISSN: 14712407     Source Type: Journal    
DOI: 10.1186/1471-2407-12-531     Document Type: Article

References (33)

1. Antoniou A, Pharoah PD, Narod S, Risch HA, Eyfjord JE, Hopper JL, Loman N, Olsson H, Johannsson O, Borg A, et al. Average risks of breast and ovarian cancer associated with BRCA1 or BRCA2 mutations detected in case Series unselected for family history: a combined analysis of 22 studies. Am J Hum Genet 2003, 72(5):1117-1130. 10.1086/375033, 1180265, 12677558.
2. King MC, Marks JH, Mandell JB. Breast and ovarian cancer risks due to inherited mutations in BRCA1 and BRCA2. Science 2003, 302(5645):643-646. 10.1126/science.1088759, 14576434.
3. Lynch HT, de la Chapelle A. Hereditary colorectal cancer. N Engl J Med 2003, 348(10):919-932. 10.1056/NEJMra012242, 12621137.
4. Umar A, Boland CR, Terdiman JP, Syngal S, de la Chapelle A, Ruschoff J, Fishel R, Lindor NM, Burgart LJ, Hamelin R, et al. Revised Bethesda Guidelines for hereditary nonpolyposis colorectal cancer (Lynch syndrome) and microsatellite instability. J Natl Cancer Inst 2004, 96(4):261-268. 10.1093/jnci/djh034, 2933058, 14970275.
5. Aarnio M, Sankila R, Pukkala E, Salovaara R, Aaltonen LA, de la Chapelle A, Peltomaki P, Mecklin JP, Jarvinen HJ. Cancer risk in mutation carriers of DNA-mismatch-repair genes. Int J Cancer 1999, 81(2):214-218. 10.1002/(SICI)1097-0215(19990412)81:2<214::AID-IJC8>3.0.CO;2-L, 10188721.
6. Baglietto L, Lindor NM, Dowty JG, White DM, Wagner A, Gomez Garcia EB, Vriends AH, Cartwright NR, Barnetson RA, Farrington SM, et al. Risks of Lynch syndrome cancers for MSH6 mutation carriers. J Natl Cancer Inst 2010, 102(3):193-201. 10.1093/jnci/djp473, 2815724, 20028993.
7. Dunlop MG, Farrington SM, Carothers AD, Wyllie AH, Sharp L, Burn J, Liu B, Kinzler KW, Vogelstein B. Cancer risk associated with germline DNA mismatch repair gene mutations. Hum Mol Genet 1997, 6(1):105-110. 10.1093/hmg/6.1.105, 9002677.
8. Bonadona V, Bonaiti B, Olschwang S, Grandjouan S, Huiart L, Longy M, Guimbaud R, Buecher B, Bignon YJ, Caron O, et al. Cancer risks associated with germline mutations in MLH1, MSH2, and MSH6 genes in Lynch syndrome. JAMA 2011, 305(22):2304-2310. 10.1001/jama.2011.743, 21642682.
9. Plaschke J, Engel C, Kruger S, Holinski-Feder E, Pagenstecher C, Mangold E, Moeslein G, Schulmann K, Gebert J, von Knebel Doeberitz M, et al. Lower incidence of colorectal cancer and later age of disease onset in 27 families with pathogenic MSH6 germline mutations compared with families with MLH1 or MSH2 mutations: the German Hereditary Nonpolyposis Colorectal Cancer Consortium. J Clin Oncol 2004, 22(22):4486-4494. 10.1200/JCO.2004.02.033, 15483016.
10. Rodriguez-Bigas MA, Boland CR, Hamilton SR, Henson DE, Jass JR, Khan PM, Lynch H, Perucho M, Smyrk T, Sobin L, et al. A National Cancer Institute Workshop on Hereditary Nonpolyposis Colorectal Cancer Syndrome: meeting highlights and Bethesda guidelines. J Natl Cancer Inst 1997, 89(23):1758-1762. 10.1093/jnci/89.23.1758, 9392616.
11. Meindl A, German Consortium for Hereditary Breast and Ovarian Cancer Comprehensive analysis of 989 patients with breast or ovarian cancer provides BRCA1 and BRCA2 mutation profiles and frequencies for the German population. Int J Cancer 2002, 97(4):472-480. German Consortium for Hereditary Breast and Ovarian Cancer.
12. Hoffman JD, Hallam SE, Venne VL, Lyon E, Ward K. Implications of a novel cryptic splice site in the BRCA1 gene. Am J Med Genet 1998, 80(2):140-144. 10.1002/(SICI)1096-8628(19981102)80:2<140::AID-AJMG10>3.0.CO;2-L, 9805131.
13. Plaschke J, Kruger S, Pistorius S, Theissig F, Saeger HD, Schackert HK. Involvement of hMSH6 in the development of hereditary and sporadic colorectal cancer revealed by immunostaining is based on germline mutations, but rarely on somatic inactivation. Int J Cancer 2002, 97(5):643-648. 10.1002/ijc.10097, 11807791.
14. Plaschke J, Kruppa C, Tischler R, Bocker T, Pistorius S, Dralle H, Ruschoff J, Saeger HD, Fishel R, Schackert HK. Sequence analysis of the mismatch repair gene hMSH6 in the germline of patients with familial and sporadic colorectal cancer. Int J Cancer 2000, 85(5):606-613. 10.1002/(SICI)1097-0215(20000301)85:5<606::AID-IJC2>3.0.CO;2-B, 10699937.
15. Engel C, Rahner N, Schulmann K, Holinski-Feder E, Goecke TO, Schackert HK, Kloor M, Steinke V, Vogelsang H, Moslein G, et al. Efficacy of annual colonoscopic surveillance in individuals with hereditary nonpolyposis colorectal cancer. Clin Gastroenterol Hepatol 2010, 8(2):174-182. 10.1016/j.cgh.2009.10.003, 19835992.
16. Borg A, Isola J, Chen J, Rubio C, Johansson U, Werelius B, Lindblom A. Germline BRCA1 and HMLH1 mutations in a family with male and female breast carcinoma. Int J Cancer 2000, 85(6):796-800. 10.1002/(SICI)1097-0215(20000315)85:6<796::AID-IJC10>3.0.CO;2-L, 10709098.
17. Thiffault I, Hamel N, Pal T, McVety S, Marcus VA, Farber D, Cowie S, Deschenes J, Meschino W, Odefrey F, et al. Germline truncating mutations in both MSH2 and BRCA2 in a single kindred. Br J Cancer 2004, 90(2):483-491. 10.1038/sj.bjc.6601424, 2409581, 14735197.
18. Win AK, Jenkins MA, Buchanan DD, Clendenning M, Young JP, Giles GG, Goldblatt J, Leggett BA, Hopper JL, Thibodeau SN, et al. Determining the frequency of de novo germline mutations in DNA mismatch repair genes. J Med Genet 2011, 48(8):530-534. 10.1136/jmedgenet-2011-100082, 3436601, 21636617.
19. Buerki N, Gautier L, Kovac M, Marra G, Buser M, Mueller H, Heinimann K. Evidence for breast cancer as an integral part of Lynch syndrome. Genes Chromosomes Cancer 2012, 51(1):83-91. 10.1002/gcc.20935, 22034109.
20. Muller A, Edmonston TB, Corao DA, Rose DG, Palazzo JP, Becker H, Fry RD, Rueschoff J, Fishel R. Exclusion of breast cancer as an integral tumor of hereditary nonpolyposis colorectal cancer. Cancer Res 2002, 62(4):1014-1019.
21. Shanley S, Fung C, Milliken J, Leary J, Barnetson R, Schnitzler M, Kirk J. Breast cancer immunohistochemistry can be useful in triage of some HNPCC families. Fam Cancer 2009, 8(3):251-255. 10.1007/s10689-008-9226-4, 19123071.
22. Walsh MD, Buchanan DD, Cummings MC, Pearson SA, Arnold ST, Clendenning M, Walters R, McKeone DM, Spurdle AB, Hopper JL, et al. Lynch syndrome-associated breast cancers: clinicopathologic characteristics of a case series from the colon cancer family registry. Clin Cancer Res 2010, 16(7):2214-2224. 10.1158/1078-0432.CCR-09-3058, 2848890, 20215533.
23. Watson P, Vasen HF, Mecklin JP, Bernstein I, Aarnio M, Jarvinen HJ, Myrhoj T, Sunde L, Wijnen JT, Lynch HT. The risk of extra-colonic, extra-endometrial cancer in the Lynch syndrome. Int J Cancer 2008, 123(2):444-449. 10.1002/ijc.23508, 2627772, 18398828.
24. Win AK, Young JP, Lindor NM, Tucker KM, Ahnen DJ, Young GP, Buchanan DD, Clendenning M, Giles GG, Winship I, et al. Colorectal and other cancer risks for carriers and noncarriers from families with a DNA mismatch repair gene mutation: a prospective cohort study. J Clin Oncol 2012, 30(9):958-964. 10.1200/JCO.2011.39.5590, 22331944.
25. Scott RJ, McPhillips M, Meldrum CJ, Fitzgerald PE, Adams K, Spigelman AD, du Sart D, Tucker K, Kirk J. Hereditary nonpolyposis colorectal cancer in 95 families: differences and similarities between mutation-positive and mutation-negative kindreds. Am J Hum Genet 2001, 68(1):118-127. 10.1086/316942, 1234904, 11112663.
26. Atchley DP, Albarracin CT, Lopez A, Valero V, Amos CI, Gonzalez-Angulo AM, Hortobagyi GN, Arun BK. Clinical and pathologic characteristics of patients with BRCA-positive and BRCA-negative breast cancer. J Clin Oncol 2008, 26(26):4282-4288. 10.1200/JCO.2008.16.6231, 18779615.
27. Thompson D, Easton DF. Cancer Incidence in BRCA1 mutation carriers. J Natl Cancer Inst 2002, 94(18):1358-1365. 10.1093/jnci/94.18.1358, 12237281.
28. Lavie O, Ben-Arie A, Segev Y, Faro J, Barak F, Haya N, Auslender R, Gemer O. BRCA germline mutations in women with uterine serous carcinoma-still a debate. Int J Gynecol Cancer 2010, 20(9):1531-1534.
29. Zhang Y, Fan S, Meng Q, Ma Y, Katiyar P, Schlegel R, Rosen EM. BRCA1 interaction with human papillomavirus oncoproteins. J Biol Chem 2005, 280(39):33165-33177. 10.1074/jbc.M505124200, 15983032.
30. Gilks CB, Prat J. Ovarian carcinoma pathology and genetics: recent advances. Hum Pathol 2009, 40(9):1213-1223. 10.1016/j.humpath.2009.04.017, 19552940.
31. Lynch HT, de la Chapelle A. Genetic susceptibility to non-polyposis colorectal cancer. J Med Genet 1999, 36(11):801-818. 1734258, 10544223.
32. Claus EB, Schildkraut JM, Thompson WD, Risch NJ. The genetic attributable risk of breast and ovarian cancer. Cancer 1996, 77(11):2318-2324. 10.1002/(SICI)1097-0142(19960601)77:11<2318::AID-CNCR21>3.0.CO;2-Z, 8635102.
33. Narod SA, Foulkes WD. BRCA1 and BRCA2: 1994 and beyond. Nat Rev Cancer 2004, 4(9):665-676. 10.1038/nrc1431, 15343273.